[{"id":"fdfde5f1-2d71-4b49-937e-9e4a41a85a52","acronym":"","url":"https://clinicaltrials.gov/study/NCT04539496","created_at":"2021-01-18T21:43:19.578Z","updated_at":"2025-02-25T17:11:32.340Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors","source_id_and_acronym":"NCT04539496","lead_sponsor":"Sihuan Pharmaceutical Holdings Group Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • letrozole • anastrozole • Xuan Yue Ning (bireociclib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 402","initiation":"Initiation: 05/22/2018","start_date":" 05/22/2018","primary_txt":" Primary completion: 07/31/2023","primary_completion_date":" 07/31/2023","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-09-13"},{"id":"36b77ad5-dd89-44e9-832d-efcd80699ed3","acronym":"BRIGHT-2","url":"https://clinicaltrials.gov/study/NCT05077449","created_at":"2021-10-14T19:57:30.329Z","updated_at":"2025-02-25T17:12:02.648Z","phase":"Phase 3","brief_title":"A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer","source_id_and_acronym":"NCT05077449 - BRIGHT-2","lead_sponsor":"Xuanzhu Biopharmaceutical Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • Xuan Yue Ning (bireociclib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 11/16/2021","start_date":" 11/16/2021","primary_txt":" Primary completion: 02/22/2024","primary_completion_date":" 02/22/2024","study_txt":" Completion: 11/01/2029","study_completion_date":" 11/01/2029","last_update_posted":"2024-05-24"},{"id":"05c164b9-0267-4191-a644-8a8df1a111ce","acronym":"","url":"https://clinicaltrials.gov/study/NCT05257395","created_at":"2022-02-25T16:52:44.137Z","updated_at":"2025-02-25T17:12:09.202Z","phase":"Phase 3","brief_title":"A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer","source_id_and_acronym":"NCT05257395","lead_sponsor":"Xuanzhu Biopharmaceutical Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • anastrozole • Xuan Yue Ning (bireociclib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 372","initiation":"Initiation: 02/01/2022","start_date":" 02/01/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2022-02-25"}]